Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 6/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | ABL1 | P00519 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | IDE | P14735 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 6/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA9 | Q16790 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5599925 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL14613464 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL5891326 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL17641197 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL14016216 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL16841483 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL23476650 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL21515957 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL22769187 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL21553555 | 1.00 | HLCS (0.68) | HLCSTDP1MEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| EP-4234689-A2 | SPLIT INTEINS WITH EXCEPTIONAL SPLICING ACTIVITY | The Trustees of Princeton University (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3405477-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023049218-A1 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-03-30 | — | — | WO | disclosed |
| US-20220396584-A1 | BIOTIN-CONTAINING MONOMERS AND ARTICLES FORMED THEREFROM | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2022-12-15 | — | — | US | disclosed |
| US-11365210-B2 | Quinone methide analog signal amplification | VENTANA MEDICAL SYSTEMS, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| WO-2022099159-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021234459-A2 | DOUBLE STRANDED OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2021-11-25 | — | — | WO | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| WO-2021105843-A1 | BIOTIN-CONTAINING MONOMERS AND ARTICLES FORMED THEREFROM | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2009040149-A1 | BIOTIN AND SILICA TO COUNTER AGEING OF HAIR | HENKEL AG & CO. KGAA (DE) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009027112-A1 | HAIR TREATMENT AGENTS | HENKEL AG & CO. KGAA (DE) | 2009-03-05 | — | — | WO | disclosed |
| EP-1313713-B1 | 4-PYRIMIDINAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS | ORTHO MCNEIL PHARM INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080003694-A1 | Robust, self-assembled, biocompatible films | TRIAD NATIONAL SECURITY, LLC | 2008-01-03 | — | — | US | disclosed |
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | ACTIVX BIOSCIENCES, INC. | 2007-06-21 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1385998-A1 | BIOMOLECULE CHARACTERIZATION USING MASS SPECTROMETRY AND AFFINITY TAGS | Ciphergen Biosystems, Inc. (US) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002086168-A1 | BIOMOLECULE CHARACTERIZATION USING MASS SPECTROMETRY AND AFFINITY TAGS | CIPHERGEN BIOSYSTEMS, INC. (US) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | HLCS 2068/4885TDP1 3276/4885MEN1 4753/4885 |
| US-20070141624-A1 | ACTIVITY-BASED PROBES AND METHODS OF THEIR PREPARATION ANS USE | DNPEP, CTRL, ARSA | HLCS 258/4885TDP1 664/4885MEN1 4670/4885 |
| US-20060167246-A1 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | TPMT, JAK2, GTF3C5 | HLCS 2842/4885TDP1 1858/4885MEN1 4852/4885 |
| US-20220396584-A1 | BIOTIN-CONTAINING MONOMERS AND ARTICLES FORMED THEREFROM | BTD, BPGM, STAMBP | HLCS 4/4885TDP1 3418/4885MEN1 2641/4885 |
| US-11365210-B2 | Quinone methide analog signal amplification | NQO2, SQOR, MRM1 | HLCS 541/4885TDP1 1222/4885MEN1 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.